235 related articles for article (PubMed ID: 30460374)
1. Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis.
Hashimoto T; Sakai K; Sanders KM; Yosipovitch G; Akiyama T
Acta Derm Venereol; 2019 Mar; 99(3):298-303. PubMed ID: 30460374
[TBL] [Abstract][Full Text] [Related]
2. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis.
Morelli M; Scarponi C; Mercurio L; Facchiano F; Pallotta S; Madonna S; Girolomoni G; Albanesi C
J Immunol Res; 2018; 2018():7897263. PubMed ID: 30581877
[TBL] [Abstract][Full Text] [Related]
3. Thymol activates TRPM8-mediated Ca
Wang W; Wang H; Zhao Z; Huang X; Xiong H; Mei Z
Toxicol Appl Pharmacol; 2020 Nov; 407():115247. PubMed ID: 32971067
[TBL] [Abstract][Full Text] [Related]
4. Role of neurturin in spontaneous itch and increased nonpeptidergic intraepidermal fiber density in a mouse model of psoriasis.
Sakai K; Sanders KM; Youssef MR; Yanushefski KM; Jensen LE; Yosipovitch G; Akiyama T
Pain; 2017 Nov; 158(11):2196-2202. PubMed ID: 28825602
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program.
Ständer S; Luger T; Cappelleri JC; Bushmakin AG; Mamolo C; Zielinski MA; Tallman AM; Yosipovitch G
Acta Derm Venereol; 2018 Mar; 98(3):340-345. PubMed ID: 29182790
[TBL] [Abstract][Full Text] [Related]
6. Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.
Fukuyama T; Ehling S; Cook E; Bäumer W
J Pharmacol Exp Ther; 2015 Sep; 354(3):394-405. PubMed ID: 26159873
[TBL] [Abstract][Full Text] [Related]
7. Mouse model of imiquimod-induced psoriatic itch.
Sakai K; Sanders KM; Youssef MR; Yanushefski KM; Jensen L; Yosipovitch G; Akiyama T
Pain; 2016 Nov; 157(11):2536-2543. PubMed ID: 27437787
[TBL] [Abstract][Full Text] [Related]
8. Imiquimod-induced pruritus in female wild-type and knockin Wistar rats: underscoring behavioral scratching in a rat model for antipruritic treatments.
Lariosa-Willingham K; Leonoudakis D; Simon F; Walker K; Guillaume P; Warren L; Stratton J
BMC Res Notes; 2023 Nov; 16(1):348. PubMed ID: 38007440
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.
Srivastava A; Ståhle M; Pivarcsi A; Sonkoly E
Acta Derm Venereol; 2018 Aug; 98(8):772-775. PubMed ID: 29738047
[TBL] [Abstract][Full Text] [Related]
10. JAK1/3 inhibition preserves epidermal morphology in full-thickness 3D skin models of atopic dermatitis and psoriasis.
Clarysse K; Pfaff CM; Marquardt Y; Huth L; Kortekaas Krohn I; Kluwig D; Lüscher B; Gutermuth J; Baron J
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):367-375. PubMed ID: 30357932
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Krueger J; Clark JD; Suárez-Fariñas M; Fuentes-Duculan J; Cueto I; Wang CQ; Tan H; Wolk R; Rottinghaus ST; Whitley MZ; Valdez H; von Schack D; O'Neil SP; Reddy PS; Tatulych S;
J Allergy Clin Immunol; 2016 Apr; 137(4):1079-1090. PubMed ID: 27059729
[TBL] [Abstract][Full Text] [Related]
12. The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development.
Stalder R; Zhang B; Jean Wrobel L; Boehncke WH; Brembilla NC
Exp Dermatol; 2020 Jan; 29(1):71-78. PubMed ID: 31721311
[TBL] [Abstract][Full Text] [Related]
13. Suppression of IL-12/IL-23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon-γ signaling in dendritic cells: Implications for the treatment of psoriasis and interferon-driven diseases.
Vincken NLA; Welsing PMJ; Silva-Cardoso SC; Bekker CPJ; Lopes AP; Olde Nordkamp M; Leijten EFA; Radstake TRDJ; Angiolilli C
Exp Dermatol; 2022 Jun; 31(6):962-969. PubMed ID: 35297512
[TBL] [Abstract][Full Text] [Related]
14. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
Artamonova OG; Karamova AE; Nikonorov AA; Verbenko DA; Vasileva EL; Kubanov AA
Bull Exp Biol Med; 2021 May; 171(2):208-211. PubMed ID: 34173094
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis.
Bagherani N; Smoller BR
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28133877
[No Abstract] [Full Text] [Related]
17. Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.
Yamamoto Y; Otsuka A; Nakashima C; Ishida Y; Honda T; Egawa G; Amano W; Usui K; Hamada Y; Wada M; Tanimoto A; Konishi N; Hayashi M; Matsushita M; Kabashima K
J Dermatol Sci; 2020 Feb; 97(2):161-164. PubMed ID: 31924380
[No Abstract] [Full Text] [Related]
18. Involvement of µ-opioid Receptors and κ-opioid Receptors in Itch-related Scratching Behaviour of Imiquimod-induced Psoriasis-like Dermatitis in Mice.
Takahashi N; Tominaga M; Kosaka R; Kamata Y; Umehara Y; Matsuda H; Sakaguchi A; Ogawa H; Takamori K
Acta Derm Venereol; 2017 Aug; 97(8):928-933. PubMed ID: 28512665
[TBL] [Abstract][Full Text] [Related]
19. Microglia-mediated chronic psoriatic itch induced by imiquimod.
Xu Z; Qin Z; Zhang J; Wang Y
Mol Pain; 2020; 16():1744806920934998. PubMed ID: 32580615
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
Feldman SR; Thaçi D; Gooderham M; Augustin M; de la Cruz C; Mallbris L; Buonanno M; Tatulych S; Kaur M; Lan S; Valdez H; Mamolo C
J Am Acad Dermatol; 2016 Dec; 75(6):1162-1170.e3. PubMed ID: 27692733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
